| REVIEW ARTICLE
|Year : 1995 | Volume
| Issue : 1 | Page : 14-29
Recent trends in hyperlipoproteinemias and its pharmacotherapy
A Ghatak, OP Asthana
Hyperlipoproteinemias cause atherosclerosis which is a major cause of death in the developed world and is also now becoming a major cause of morbidity and mortality in India, especially with changing lifestyles and increasing stress and food habits shifting towards the "fast food" era. It is extremely important to understand the risk factors, the criteria for starting treatment, the efficacy and safety profile of drugs for hyperlipoproteinemia and the drugs which are available for pharmacotherapy especially in the Indian perspective. The significant contributions of Central Drug Research Institute, Lucknow in developing potent lipid lowering drugs like Gugulipid an already marketed product and a new synthetic drug coded as compound 80/574 in the early phase of clinical trials have been specially discussed in this article. At present it is recommended that for mild to moderate hyperlipoproteinemia Gugulipid would be an extremely cost effective indigenous choice and with the further development of the new CDRI compound 80/574 even moderate to severe hyperlipoproteinemia would be manageable. The other alternatives like Gemfibrozil though highly effective for moderate to severe hyperlipoproteinemia are extremely expensive and have other side effects and only very few can afford to take it on long term basis in India.
Source of Support: None, Conflict of Interest: None